MA33092B1 - Forme cristalline du dihydrogénophosphate de (r)-3-(4-(2-(2-méthyltétrazol-5-yl)pyridin-5-yl)-3-fluorophényl)-5-hydroxyméthyl oxazolidin-2-one - Google Patents

Forme cristalline du dihydrogénophosphate de (r)-3-(4-(2-(2-méthyltétrazol-5-yl)pyridin-5-yl)-3-fluorophényl)-5-hydroxyméthyl oxazolidin-2-one

Info

Publication number
MA33092B1
MA33092B1 MA34136A MA34136A MA33092B1 MA 33092 B1 MA33092 B1 MA 33092B1 MA 34136 A MA34136 A MA 34136A MA 34136 A MA34136 A MA 34136A MA 33092 B1 MA33092 B1 MA 33092B1
Authority
MA
Morocco
Prior art keywords
crystalline form
pyridin
fluorophenyl
dihydrogenophosphate
methyltetrazol
Prior art date
Application number
MA34136A
Other languages
English (en)
Inventor
Robert J Duguid
Douglas Phillipson
Jacqueline A Ware
Katharina Reichenbacher
Original Assignee
Trius Therapeutics
Abu Ghazaleh Intellectual Prop
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42289775&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33092(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Trius Therapeutics, Abu Ghazaleh Intellectual Prop filed Critical Trius Therapeutics
Publication of MA33092B1 publication Critical patent/MA33092B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'INVENTION CONCERNE UNE FORME CRISTALLINE DU DIHYDROGÉNOPHOSPHATE DE (R)-3-(4-(2-(2-MÉTHYLTÉTRAZOL-5-YL)-PYRIDIN-5-YL)-3-FLUOROPHÉNYL)-5-HYDROXYMÉTHYL OXAZOLIDIN-2-ONE, DES PROCÉDÉS DE PRÉPARATION DE LA FORME CRISTALLINE ET DES COMPOSITIONS CONTENANT LA FORME CRISTALLINE UTILES COMME ANTIBIOTIQUES. EN OUTRE, LES DÉRIVÉS DE LA PRÉSENTE INVENTION PEUVENT EXERCER UNE PUISSANTE ACTIVITÉ ANTIBACTÉRIENNE SUR DIVERS PATHOGÈNES HUMAINS ET ANIMAUX, NOTAMMENT SUR LES BACTÉRIES GRAM-POSITIVES TELLES QUE LES STAPHYLOCOQUES, LES ENTÉROCOQUES ET LES STREPTOCOQUES, LES MICRO-ORGANISMES ANAÉROBIES TELS QUE LES BACTÉROIDES ET LES CLOSTRIDIA, ET LES MICRO-ORGANISMES ACIDO-RÉSISTANTS TELS QUE MYCOBACTERIUM TUBERCULOSIS ET MYCOBACTERIUM AVIUM. LES COMPOSITIONS CONTENANT LA FORME CRISTALLINE PEUVENT DONC ÊTRE UTILISÉES COMME ANTIBIOTIQUES.
MA34136A 2009-02-03 2010-02-03 Forme cristalline du dihydrogénophosphate de (r)-3-(4-(2-(2-méthyltétrazol-5-yl)pyridin-5-yl)-3-fluorophényl)-5-hydroxyméthyl oxazolidin-2-one MA33092B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14940209P 2009-02-03 2009-02-03
PCT/US2010/023122 WO2010091131A1 (fr) 2009-02-03 2010-02-03 Forme cristalline du dihydrogénophosphate de (r)-3-(4-(2-(2-méthyltétrazol-5-yl)pyridin-5-yl)-3-fluorophényl)-5-hydroxyméthyl oxazolidin-2-one

Publications (1)

Publication Number Publication Date
MA33092B1 true MA33092B1 (fr) 2012-03-01

Family

ID=42289775

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34136A MA33092B1 (fr) 2009-02-03 2010-02-03 Forme cristalline du dihydrogénophosphate de (r)-3-(4-(2-(2-méthyltétrazol-5-yl)pyridin-5-yl)-3-fluorophényl)-5-hydroxyméthyl oxazolidin-2-one

Country Status (29)

Country Link
US (6) US8426389B2 (fr)
EP (1) EP2393808B1 (fr)
JP (1) JP5584705B2 (fr)
KR (3) KR101739923B1 (fr)
CN (2) CN102439006A (fr)
AP (1) AP2987A (fr)
AU (1) AU2010210627B2 (fr)
BR (1) BRPI1008829A2 (fr)
CA (1) CA2751392C (fr)
CL (1) CL2011001855A1 (fr)
CO (1) CO6620071A2 (fr)
CR (1) CR20110464A (fr)
CU (1) CU24089B1 (fr)
DO (1) DOP2011000251A (fr)
EC (1) ECSP11011285A (fr)
ES (1) ES2734724T3 (fr)
IL (1) IL214401B (fr)
MA (1) MA33092B1 (fr)
MX (3) MX2011008093A (fr)
MY (1) MY156354A (fr)
NZ (3) NZ620458A (fr)
PE (1) PE20120585A1 (fr)
PH (1) PH12014500092A1 (fr)
RU (2) RU2655928C1 (fr)
SG (2) SG173497A1 (fr)
TN (1) TN2011000381A1 (fr)
UA (1) UA114068C2 (fr)
WO (1) WO2010091131A1 (fr)
ZA (2) ZA201106412B (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100854211B1 (ko) 2003-12-18 2008-08-26 동아제약주식회사 신규한 옥사졸리디논 유도체, 그의 제조방법 및 이를유효성분으로 하는 항생제용 약학 조성물
MX2011003820A (es) 2008-10-10 2011-06-16 Trius Therapeutics Metodos para preparar oxazolidinonas y composiciones que las contienen.
SG173497A1 (en) 2009-02-03 2011-09-29 Trius Therapeutics Crystalline form of r)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate
US8580767B2 (en) * 2009-05-28 2013-11-12 Trius Therapeutics, Inc. Oxazolidinone containing dimer compounds, compositions and methods to make and use
WO2013059610A1 (fr) 2011-10-20 2013-04-25 Trius Therapeutics, Inc. Polythérapie de daptomycine et d'un antibiotique inhibiteur de la synthèse protéique, et ses procédés d'utilisation
WO2015054246A1 (fr) * 2013-10-07 2015-04-16 Trius Therapeutics, Inc. Procédés de traitement de sujets présentant une insuffisance rénale à l'aide de tédizolid
WO2015158202A1 (fr) * 2014-04-18 2015-10-22 杭州普晒医药科技有限公司 Forme cristalline d'antibiotiques à base d'oxazolidinione, son procédé de préparation, sa composition pharmaceutique et son utilisation
WO2016009401A2 (fr) * 2014-07-18 2016-01-21 Dr. Reddy's Laboratories Limited Préparation du phosphate de tédizolid
CN104327119A (zh) * 2014-10-17 2015-02-04 苏州明锐医药科技有限公司 磷酸泰地唑胺的制备方法
WO2016063246A1 (fr) * 2014-10-22 2016-04-28 Sun Pharmaceutical Industries Limited Forme cristalline r de phosphate de tédizolide
WO2016088102A1 (fr) * 2014-12-05 2016-06-09 Sun Pharmaceutical Industries Limited Procédés pour la préparation de tedizolid et de ses intermédiaires
WO2016088100A1 (fr) * 2014-12-05 2016-06-09 Sun Pharmaceutical Industries Limited Procédés pour préparer un phosphate de tédizolid et ses intermédiaires
WO2016088101A1 (fr) * 2014-12-05 2016-06-09 Sun Pharmaceutical Industries Limited Procédés de préparation de phosphate de tédizolide et de ses intermédiaires
CZ306245B6 (cs) * 2014-12-11 2016-10-26 Univerzita Karlova v Praze Farmaceutická fakulta v Hradci Králové Substituovaný fenyltetrazol, jeho použití a farmaceutický přípravek ho obsahující
CN104558034A (zh) * 2015-01-21 2015-04-29 齐鲁制药有限公司 磷酸特地唑胺二钠盐的新晶型及其制备方法
CN105837634B (zh) * 2015-01-30 2020-09-04 上海创诺制药有限公司 一种泰地唑胺磷酸酯结晶体及其制备方法
CN104592218B (zh) * 2015-02-13 2015-11-04 江苏欧信医药化工有限公司 一种泰地唑胺的合成方法
CN106146485B (zh) * 2015-04-01 2021-04-30 上海迪赛诺化学制药有限公司 一种制备泰地唑胺的方法及其得到的泰地唑胺结晶体
CN106146558A (zh) * 2015-04-10 2016-11-23 博瑞生物医药（苏州）股份有限公司 新的噁唑烷酮类化合物及其制备方法
CN106317114B (zh) * 2015-07-02 2018-11-20 南京优科制药有限公司 一种磷酸特地唑胺的制备方法
CN105085570B (zh) * 2015-09-12 2017-11-28 山东罗欣药业集团股份有限公司 一种磷酸特地唑胺化合物及其制备方法
CN105287407B (zh) * 2015-11-24 2018-09-21 南京正大天晴制药有限公司 一种注射用磷酸特地唑胺
CN107121503B (zh) * 2017-03-14 2020-04-28 南京优科制药有限公司 一种磷酸特地唑胺及其有关物质的分析方法
CN108948079A (zh) * 2017-05-17 2018-12-07 上海奥博生物医药技术有限公司 一种特地唑胺二铵盐及晶型与其制备方法
EP3723758A4 (fr) * 2017-12-13 2021-06-23 Merck Sharp & Dohme Corp. Compositions pharmaceutiques de tedizolid phosphate
KR102777328B1 (ko) 2018-07-25 2025-03-10 자이두스 라이프사이언시즈 리미티드 포유류 감염 치료를 위한 신규 화합물
WO2021258013A1 (fr) 2020-06-18 2021-12-23 Akagera Medicines, Inc. Composés du type oxazolidinone, compositions de liposome comprenant des composés du type oxazolidinone et méthodes d'utilisation associées
CN112957332B (zh) * 2021-02-04 2023-04-25 海南通用康力制药有限公司 注射用磷酸特地唑胺及其质量标准
CN112957333B (zh) * 2021-02-05 2022-11-22 海南通用康力制药有限公司 注射用磷酸特地唑胺及其制备方法
CN113197874B (zh) * 2021-04-28 2023-05-26 北京福元医药股份有限公司 一种磷酸特地唑胺口服固体制剂

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU80081A1 (fr) * 1977-08-26 1979-05-15 Delalande Sa Nouvelles hydroxymethyl-5 oxazolidinones-2,leur procede de preparation et leur application therapeutique
US4128654A (en) * 1978-02-10 1978-12-05 E. I. Du Pont De Nemours And Company 5-Halomethyl-3-phenyl-2-oxazolidinones
US4340606A (en) * 1980-10-23 1982-07-20 E. I. Du Pont De Nemours And Company 3-(p-Alkylsulfonylphenyl)oxazolidinone derivatives as antibacterial agents
FR2500450A1 (fr) * 1981-02-25 1982-08-27 Delalande Sa Nouveaux derives aminomethyl-5 oxazolidiniques, leur procede de preparation et leur application en therapeutique
US4461773A (en) * 1982-09-15 1984-07-24 E. I. Dupont De Nemours And Company P-Oxooxazolidinylbenzene compounds as antibacterial agents
CA1320730C (fr) 1987-10-16 1993-07-27 The Du Pont Merck Pharmaceutical Company Derives d'aminomethyloxooxazolidinylaroylbenzene, agents antibacteriens
US4948801A (en) 1988-07-29 1990-08-14 E. I. Du Pont De Nemours And Company Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents
US5254577A (en) 1988-07-29 1993-10-19 The Du Pont Merck Pharmaceutical Company Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents
US5144911A (en) * 1990-11-28 1992-09-08 Moore Cheri L Component bed system for a pet
ATE146783T1 (de) 1991-11-01 1997-01-15 Upjohn Co Substituierte aryl- und heteroaryl- phenyloxazolidinone
SK283420B6 (sk) 1992-05-08 2003-07-01 Pharmacia & Upjohn Company Antimikrobiálne oxazolidinóny obsahujúce substituované diazínové skupiny
PL175782B1 (pl) * 1992-12-08 1999-02-26 Upjohn Co Nowe podstawione troponem pochodne fenylooksazolidynonowe
MY115155A (en) 1993-09-09 2003-04-30 Upjohn Co Substituted oxazine and thiazine oxazolidinone antimicrobials.
US5688792A (en) * 1994-08-16 1997-11-18 Pharmacia & Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials
WO1995014684A1 (fr) * 1993-11-22 1995-06-01 The Upjohn Company Esters d'hydroxyacetyl-piperazine-phenyl-oxazolidinones substituees
GB9702213D0 (en) * 1996-02-24 1997-03-26 Zeneca Ltd Chemical compounds
US6413981B1 (en) 1999-08-12 2002-07-02 Ortho-Mcneil Pharamceutical, Inc. Bicyclic heterocyclic substituted phenyl oxazolidinone antibacterials, and related compositions and methods
GB0009803D0 (en) * 2000-04-25 2000-06-07 Astrazeneca Ab Chemical compounds
JP2003535860A (ja) 2000-06-05 2003-12-02 ドン・ア・ファーム・カンパニー・リミテッド 新規なオキサゾリジノン誘導体及びその製造方法
US20020115669A1 (en) * 2000-08-31 2002-08-22 Wiedeman Paul E. Oxazolidinone chemotherapeutic agents
YU52403A (sh) 2000-12-26 2006-03-03 Dr.Reddy's Research Foundation Heterociklična jedinjenja koja imaju antibakterijsko dejstvo, postupak za njihovo dobijanje i farmaceutske smeše koje ih sadrže
US20050032861A1 (en) 2001-04-07 2005-02-10 Betts Michael John Oxazolidines containing a sulfonimid group as antibiotics
US6623140B2 (en) 2001-04-13 2003-09-23 Scott R. Watterson Illumination device having multiple light sources
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
CA2459766A1 (fr) 2001-09-11 2003-03-20 Astrazeneca Ab Oxazolidinone et/ou isoxazoline utilises comme agents antibacteriens
DE60210654T2 (de) 2001-10-25 2007-01-25 Astrazeneca Ab Aryl substituierte oxazolidinone mit antibacterieller activität
NZ515881A (en) 2001-12-03 2004-09-24 New Zealand Dairy Board Cheese flavour ingredient and method of its production
AR038536A1 (es) * 2002-02-25 2005-01-19 Upjohn Co N-aril-2-oxazolidinona-5- carboxamidas y sus derivados
RU2004129278A (ru) 2002-02-28 2005-06-10 Астразенека Аб (Se) Химические соединения
US7473699B2 (en) 2002-02-28 2009-01-06 Astrazeneca Ab 3-cyclyl-5-(nitrogen-containing 5-membered ring)methyl-oxazolidinone derivatives and their use as antibacterial agents
MXPA05005651A (es) * 2002-11-28 2005-07-27 Astrazeneca Ab Derivados de oxazolidinona y/o isoxazolina como agentes antibacterianos.
EP1581524A2 (fr) 2002-11-28 2005-10-05 AstraZeneca AB Derives d`oxazolidinones comme agents bactericides
US7202257B2 (en) * 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
US7144911B2 (en) * 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
TW200500360A (en) * 2003-03-01 2005-01-01 Astrazeneca Ab Hydroxymethyl compounds
GB0306358D0 (en) 2003-03-20 2003-04-23 Astrazeneca Ab Chemical compounds
AU2004256085B2 (en) * 2003-07-02 2007-12-06 Kyorin, Pharmaceutical Co., Ltd. Cyclopropyl Group Substituted Oxazolydinone Antibiotics and Derivatives Thereof
ATE471937T1 (de) 2003-07-02 2010-07-15 Merck Sharp & Dohme Cyclopropylgruppensubstituierte oxazolidinonantibiotika und derivate davon
NZ529860A (en) 2003-11-28 2006-10-27 Ovita Ltd Muscle growth regulator mighty and use in promoting muscle mass and treating muscle wasting diseases
WO2005051933A1 (fr) 2003-11-28 2005-06-09 Ranbaxy Laboratories Limited Procede ameliore de synthese d'ester test-butylique d'acide 4-(4-benzyloxy-carbonylamino-2-fluorophenyl)-piperazine-1-carboxylique, compose intermediaire cle de la preparation d'agents antimicrobiens a l'oxazolidinone, et composes ainsi prepares
TW200526649A (en) * 2003-12-17 2005-08-16 Rib X Pharmaceuticals Inc Halogenated biaryl heterocyclic compounds and methods of making and using the same
KR100854211B1 (ko) * 2003-12-18 2008-08-26 동아제약주식회사 신규한 옥사졸리디논 유도체, 그의 제조방법 및 이를유효성분으로 하는 항생제용 약학 조성물
US20070191336A1 (en) * 2003-12-24 2007-08-16 Flynn Daniel L Anti-inflammatory medicaments
GB0411596D0 (en) 2004-05-25 2004-06-30 Astrazeneca Ab Chemical process
AU2005247671A1 (en) * 2004-05-25 2005-12-08 Astrazeneca Ab 3- (4- (2-dihydroisoxazol-3-ylpyridin-5-yl) phenyl) -5-triazol-1-ylmethyloxazolidin-2-one derivaives as MAO inhibitors for the treatment of bacterial infections
US20080064689A1 (en) * 2004-05-25 2008-03-13 Astrazeneca Ab 3-[4-(6-Pyridin-3-Yl)-3-Phenyl] -5-(1H-1,2,3-Triazol-1-Ylmethyl)-1,3-Oxazolidin-2-Ones as Antibacterial Agents
JP2008500318A (ja) * 2004-05-25 2008-01-10 アストラゼネカ アクチボラグ 抗菌剤としての３−｛４−（ピリジン−３−イル）フェニル｝−５−（１ｈ−１，２，３−トリアゾール−１−イルメチル）−１，３−オキサゾリジン−２−オン
JP2008500317A (ja) * 2004-05-25 2008-01-10 アストラゼネカ アクチボラグ 抗菌剤としての３−’４−｛６−置換アルカノイル）ピリジン−３−イル｝−３−フェニル−５−（１ｈ−１，２，３−トリアゾール−１−イルメチル）−１，３−オキサゾリジン−２−オン
EP1799677A1 (fr) 2004-10-08 2007-06-27 Ranbaxy Laboratories Limited Derives d'oxazolidinone utilises comme agents antimicrobiens
WO2007023507A2 (fr) 2005-06-20 2007-03-01 Wockhardt Limited Composition a activite antimicrobienne supportant des oxazolidinones ainsi que procedes de preparation associes
WO2007138381A2 (fr) 2005-10-14 2007-12-06 Targanta Therapeutics Inc. Oxazolidinones phosphonées et leurs utilisations pour la prévention et le traitement des infections des os et des articulations
WO2009020616A1 (fr) * 2007-08-06 2009-02-12 Micurx Pharmaceuticals, Inc. Orthofluorophényle oxazolidinones antimicrobiennes pour le traitement d'infections bactériennes
CN101220001A (zh) * 2008-01-25 2008-07-16 浙江博泰化工有限公司 一种利奈唑酮的合成方法
MX2011003820A (es) 2008-10-10 2011-06-16 Trius Therapeutics Metodos para preparar oxazolidinonas y composiciones que las contienen.
SG173497A1 (en) 2009-02-03 2011-09-29 Trius Therapeutics Crystalline form of r)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate
US8580767B2 (en) 2009-05-28 2013-11-12 Trius Therapeutics, Inc. Oxazolidinone containing dimer compounds, compositions and methods to make and use

Also Published As

Publication number Publication date
EP2393808B1 (fr) 2019-05-08
CA2751392C (fr) 2017-03-28
CR20110464A (es) 2016-07-20
IL214401A0 (en) 2011-09-27
TN2011000381A1 (en) 2013-03-27
WO2010091131A1 (fr) 2010-08-12
ECSP11011285A (es) 2011-10-31
MX384300B (es) 2025-03-14
SG10201500207QA (en) 2015-03-30
US10065947B1 (en) 2018-09-04
CU24089B1 (es) 2015-04-29
JP5584705B2 (ja) 2014-09-03
KR101918678B1 (ko) 2018-11-14
US10442829B2 (en) 2019-10-15
AU2010210627A1 (en) 2011-08-25
ZA201106412B (en) 2013-11-27
US8426389B2 (en) 2013-04-23
US20130310343A1 (en) 2013-11-21
PE20120585A1 (es) 2012-06-13
ES2734724T3 (es) 2019-12-11
KR20170040371A (ko) 2017-04-12
SG173497A1 (en) 2011-09-29
NZ594408A (en) 2014-03-28
AU2010210627B2 (en) 2016-03-03
US20170275315A1 (en) 2017-09-28
NZ712289A (en) 2017-03-31
CN107082790A (zh) 2017-08-22
CU20110155A7 (es) 2012-02-15
US20160176905A1 (en) 2016-06-23
US9624250B2 (en) 2017-04-18
MX2020011773A (es) 2020-11-24
RU2655928C1 (ru) 2018-05-30
MX2011008093A (es) 2011-11-29
EP2393808A1 (fr) 2011-12-14
BRPI1008829A2 (pt) 2016-03-15
RU2011136537A (ru) 2013-03-10
AP2011005835A0 (en) 2011-08-31
PH12014500092B1 (en) 2014-12-01
MY156354A (en) 2016-02-15
AP2987A (en) 2014-09-30
ZA201306536B (en) 2014-05-28
US9988406B2 (en) 2018-06-05
UA114068C2 (xx) 2017-04-25
JP2012516894A (ja) 2012-07-26
US20180244704A1 (en) 2018-08-30
KR20110120311A (ko) 2011-11-03
CN102439006A (zh) 2012-05-02
US20180251482A1 (en) 2018-09-06
CL2011001855A1 (es) 2011-11-11
NZ620458A (en) 2015-10-30
CA2751392A1 (fr) 2010-08-12
US20100227839A1 (en) 2010-09-09
DOP2011000251A (es) 2011-11-15
PH12014500092A1 (en) 2014-12-01
CO6620071A2 (es) 2013-02-15
KR20170135984A (ko) 2017-12-08
KR101739923B1 (ko) 2017-05-25
IL214401B (en) 2021-03-25

Similar Documents

Publication Publication Date Title
MA33092B1 (fr) Forme cristalline du dihydrogénophosphate de (r)-3-(4-(2-(2-méthyltétrazol-5-yl)pyridin-5-yl)-3-fluorophényl)-5-hydroxyméthyl oxazolidin-2-one
LU92834I2 (fr) Tédizolide, optionnellement sous la forme d'un ester, en particulier un phosphate ou un sel de celui-ci pharmaceutiquement acceptable
MA32615B1 (fr) Inhibiteurs de cmet
MA37383A1 (fr) Compose heterobicycliques comme inhibiteurs de la beta lactamase
MA31151B1 (fr) Inhibiteurs de mapk/erk kinase
CL2004000400A1 (es) Compuestos derivados de piridina sustituida con 1,3-oxazol y con isoxazol, composicion farmaceutica, procedimiento de preparacion, utiles como agentes antibacteriano, activo contra la bacteria gram negativa.
AU3889095A (en) Bicyclic oxazine and thiazine oxazolidinone antibacterials
CA2236677A1 (fr) Derives de 4-pyrimidinyl- ou 4-pyrazinyl-piperazinyl-phenyl-oxazolidinone, leur preparation et leur emploi comme agents antibacteriens
BR0112826A (pt) Derivados da oxazolidinona como antimicrobianos
EP1946760A4 (fr) Composition destinée à améliorer la flore intestinale
MA30717B1 (fr) Derives de pyridin-3-yle en tant qu'agents immunomodulateurs
TW200507848A (en) Hiv integrase inhibitors
EP1409465A4 (fr) Derives d'oxazolidinone comme antimicrobiens
BR0215921A (pt) Derivados de oxazolidinona utilizáveis como antimicrobianos e processo de sua preparação
WO2017011730A3 (fr) Dérivés de phénazine utilisés comme agents antimicrobiens
WO2010058423A9 (fr) Nouveaux agents antimicrobiens
WO2009154785A3 (fr) Apha-céto oxazoles substituées en c4
PE20060942A1 (es) Derivados nonadepsipeptidos acilados ii como agentes bactericidas
ATE504333T1 (de) Behandlung mykobakterieller infektionen mit cyclipostinen
JO3077B1 (ar) مشتقات كوينولين مضادة للبكتيريا
WO2007102061A3 (fr) Promédicaments d'acide benzoquinolizine-2-carboxylique
MY127336A (en) Container for linezolid iv solution
PE20060619A1 (es) Derivados de oxazolidinona como antibacterianos
MX2008000079A (es) Derivados de quinolina como agentes antibacterianos.
WO2006018682A3 (fr) Derives d'oxazolidinone comme antimicrobiens